BRM521
/ BRIM Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 30, 2024
COMBINED BRM521 AND HUMAN MESENCHYMAL STEM CELL TREATMENT IMPROVES ARTICULAR CARTILAGE PATHOLOGY CHANGE IN THE ANTERIOR CRUCIATE LIGAMENT TRANSECTION INDUCED MOUSE OSTEOARTHRITIS MODEL
(OARSI 2024)
- "Purpose (the aim of the study): The aim of this study was to investigate the effect of combined treatment with BRM521 and hMSC on improving osteoarthritis pathogenesis."
Preclinical • Immunology • Osteoarthritis • Pain • Rheumatology
1 to 1
Of
1
Go to page
1